EXTEND III: Efficacy and safety of ranibizumab in South Korean and Taiwanese patients with subfoveal CNV secondary to AMD

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 250, Issue 10, 2012, Pages 1467-1476

  Kwon, Oh Woong ^a   Lee, Fenq Lih ^b   Chung, Hum ^c   Lai, Chi Chun ^d   Sheu, Shwu Jiuan ^e   Yoon, Young Hee ^f  

^a NUNE Eye Hospital   (South Korea)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c Seoul National University Hospital   (South Korea)

^d CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f Asan Medical Center   (South Korea)

Author keywords

Age related macular degeneration; Best corrected visual acuity; Choroidal neovascularization; Fluorescein leakage; Intravitreal ranibizumab

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; ASTHMA; BLOOD PRESSURE REGULATION; CATARACT; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; ETHNIC DIFFERENCE; FEMALE; GLAUCOMA; HUMAN; HYPEREMIA; HYPERTENSION; INGUINAL HERNIA; INJECTION SITE PAIN; INTERVERTEBRAL DISK HERNIA; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROLITHIASIS; OCCLUSIVE CEREBROVASCULAR DISEASE; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PANCREAS CARCINOMA; PERIODONTITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RHINOPHARYNGITIS; SIDE EFFECT; SOUTH KOREA; SUBRETINAL NEOVASCULARIZATION; SYNDROME DELINEATION; TAIWAN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTEBRAL CANAL STENOSIS; VESTIBULAR NEURONITIS; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CAPILLARY PERMEABILITY; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; REPUBLIC OF KOREA; TAIWAN; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 84867741992     PISSN: 0721832X     EISSN: 1435702X     Source Type: Journal    
DOI: 10.1007/s00417-012-1970-3     Document Type: Article

References (17)

1. WHO. Magnitude and causes of visual impairment [fact sheet no. 282]. Geneva: World Health Organization. URL http://www.who. int/mediacentre/ factsheets/fs282/en/. Accessed on August 01, 2011
2. Bhisitkul RB (2006) Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol 90:1542-1547
3. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA, Li W, Connolly E, O'Neill CA, Miller JW (2002) Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 120:338-346
4. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO (2003) Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 22:1-29
5. Ferrara N, Damico L, Shams N, Lowman H, Kim R (2006) Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular agerelated macular degeneration. Retina 26:859-870
6. Lowe J, Araujo J, Yang J, Reich M, Oldendorp A, Shiu V, Quarmby V, Lowman H, Lien S, Gaudreault J, Maia M (2007) Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 85:425-430
7. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432-1444
8. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419-1431
9. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T (2009) Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 116:57-65, e5
10. Tano Y, Ohji M (2010) EXTEND-I: safety and efficacy of ranibizumab in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Acta Ophthalmol 88:309-316
11. Hsu WM, Cheng CY, Liu JH, Tsai SY, Chou P (2004) Prevalence and causes of visual impairment in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology 111:62-69
12. Liu JH, Cheng CY, Chen SJ, Lee FL (2001) Visual impairment in a Taiwanese population: prevalence, causes, and socioeconomic factors. Ophthalmic Epidemiol 8:339-350
13. Miyazaki M, Nakamura H, Kubo M, Kiyohara Y, Oshima Y, Ishibashi T, Nose Y (2003) Risk factors for age related maculopathy in a Japanese population: the Hisayama Study. Br J Ophthalmol 87:469-472
14. Wong TY, Loon SC, Saw SM (2006) The epidemiology of age related eye diseases in Asia. Br J Ophthalmol 90:506-511
15. Lee FL, Kwon OW, Chung H, Lai CC, Sheu SJ, Yoon YH, EXTEND III Study Group (2012) Ranibizumab in South Korean and Taiwanese patients with age-related macular degeneration: primary outcome of the EXTEND III study. Acta Ophthalmol [Epub ahead of print]. doi:10.1111/j.1755-3768.2011.02262.x
16. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR (2007) Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 144:850-857
17. Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G; Treatment of Age-relatedMacular Degeneration with Photodynamic Therapy study group; Verteporfin in Photodynamic Therapy study group (2003) Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol 136:407-418